Advertisement

Topics

Amryt Pharma making major advances after successful Lojuxta trial

04:36 EDT 9 Aug 2017 | Proactive Investors

Dr Helen Phillips, head of medical affairs at Amryt Pharma PLC (LON:AMYT) discusses with Proactive a recently published long-term study of the drug Lojuxta which further confirmed its efficacy in lowering high cholesterol levels resulting from a rare genetic disorder.

The assessment of Lojuxta, also known as lomitapide, followed the progress of patients with Homozygous Familial Hypercholesterolaemia (HoFH).

Original Article: Amryt Pharma making major advances after successful Lojuxta trial

NEXT ARTICLE

More From BioPortfolio on "Amryt Pharma making major advances after successful Lojuxta trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Hyperlipidemia - high cholesterol (hypercholesterolaemia)
Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Lipids are transported in a protein capsule, the size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type...